Načítá se...
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
BACKGROUND: Programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy fails in the majority of patients with cancer. Oncolytic viruses represent a new class of therapeutic agents, yet the therapeutic efficacy is still disappointing. Moreover, intratumoral injection of viruses...
Uloženo v:
| Vydáno v: | J Immunother Cancer |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7254155/ https://ncbi.nlm.nih.gov/pubmed/32461344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000294 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|